An interesting trading halt announcement for Imugene indeed.
It’s not as if they need cash, they have plenty of that to see them through several years of trials. Enough to see them through all currently planned trials in fact.
Hence I can only accept either:
- the terms are very favourable to Imugene, or
- some big players are very interested, maybe even a partnership, or
- Imugene plan to either accelerate current trials, or introduce new ones.
Either way, it seems good—although there will be dilution unless a current holder is selling to the new. That will be bitter sweet, but still positive IMHO. The more big players interested, the merrier in my eyes.